Effect of clodronate on gene expression in the peripheral blood of horses
Journal of Veterinary Pharmacology and Therapeutics · 2024
DOI: 10.1111/jvp.13424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2024. Verfasst von Callie V Wilcox und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, California, USA. Hauptthemen laut MEDLINE: Clodronic Acid, Bone Density Conservation Agents, Gene Expression Regulation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, Grayson-Jockey Club Research Foundation.
Abstract (Originalsprache)
There are two FDA‐approved bisphosphonate products, clodronate (Osphos®) and tiludronate (Tildren®), for use in horses. It is hypothesized that bisphosphonates can produce analgesic effects and prevent proper healing of microcracks in bone. Therefore, bisphosphonate use is banned in racehorses. However, bisphosphonates have a short detection window in the blood before sequestration in the skeleton, making the reliability of current drug tests questionable. Seven exercising Thoroughbred horses were administered clodronate (1.8 mg/kg i.m.), and four were administered saline. RNA was isolated from peripheral blood mononuclear cells (PBMCs) collected immediately before a single dose of clodronate or saline and then on Days 1, 6, 28, 56 and 182 post‐dose. mRNA was sequenced and analysed for differentially expressed transcripts. While no single transcripts were differentially expressed, pathway analysis revealed that p38 MAPK ( p = .04) and Ras ( p = .04) pathways were upregulated, and cadherin signalling ( p = .02) was downregulated on Day 1. Previously investigated biomarkers, cathepsin K ( CTSK ) and type 5 acid phosphatase ( ACP5 ), were analysed with RT‐qPCR in a targeted gene approach, with no significant difference observed. A significant effect of time on gene expression for ACP5 ( p = .03) and CTSK ( p < .0001) was observed. Thus, these genes warrant further investigation for detecting clodronate use over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, California, USA.
- K. L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, California, USA.
- Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California, USA.
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, California, USA.
- School of Veterinary Medicine, University of California, Davis, California, USA.
ORCID-Profile: Callie V Wilcox, Heather K Knych, Carrie J Finno
Förderung
- NCATS NIH HHS
- NIH HHS
- Grayson-Jockey Club Research Foundation
Zitieren
APA
Wilcox, C. V., Knych, H. K., Katzman, S. A., Arthur, R. M., Rodriguez, V., & Finno, C. J. (2024). Effect of clodronate on gene expression in the peripheral blood of horses. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13424
Vancouver
Wilcox CV, Knych HK, Katzman SA, Arthur RM, Rodriguez V, Finno CJ. Effect of clodronate on gene expression in the peripheral blood of horses. Journal of Veterinary Pharmacology and Therapeutics. 2024. doi:10.1111/jvp.13424
BibTeX
@article{Wilcox2024,
author = {Wilcox, Callie V and Knych, Heather K and Katzman, Scott A and Arthur, Rick M and Rodriguez, Veronika and Finno, Carrie J},
title = {Effect of clodronate on gene expression in the peripheral blood of horses},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2024},
doi = {10.1111/jvp.13424}
}
EUVIMED